Cocrystal Pharma selected lead compound for further development against Coronaviruses
On Dec. 22, 2020, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…
-
-
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…
-
RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model
On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
-
Aurinia and Lonza announced exclusive agreement for dedicated Voclosporin manufacturing capacity
On Dec. 15, 2020, Aurinia Pharmaceuticals announced the funding and initiation of an open-label exploratory trial evaluating the…
-
Bankruptcy judge approved federal settlement with Purdue Pharma
On Nov. 17, 2020, the proposed settlements between the federal government and OxyContin maker Purdue Pharma and its…
-
Seagen announced closing of $1.0 billion stock sale to Merck
On Oct. 28, 2020, Seagen announced the closing of a $1.0 billion equity investment by Merck in 5.0…
-
Purdue Pharma reached agreement with U.S. Department of Justice
On Oct. 21, 2020, Purdue Pharma announced that it had entered into an agreement with the U.S. Department…
-
Agriculture | Artificial Intelligence | Biotechnology | CMO | CRO | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
U.S. Department of Defense approved $87 million for newest bioindustrial manufacturing innovation institute
On Oct. 20, 2020, the U.S. Department of Defense announced an $87 million, seven-year award to the BioIndustrial…
-
Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
-
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
-
RedHill Biopharma’s Opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
-
Data from Corvus phase 1 study of CPI-006 continued to support its potential as treatment for COVID-19
On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Pharmaceutical | Therapeutics | Vaccine | WHO
WHO welcomed $90 million contribution from Kingdom of Saudi Arabia to support COVID-19 global response
On Oct. 2, 2020, the World Health Organization (WHO) and the Kingdom of Saudi Arabia signed a contribution…
-
New anti-infective drugs had a 14% speed advantage vs other drugs from 2000-2019
On Sept. 15, 2020, the Tufts Center for the Study of Drug Development reported that new anti-infective drugs…
-
RedHill Biopharma’s opaganib demonstrated complete inhibition of SARS-CoV-2
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
-
Mesoblast announced first patients dosed in phase 2/3 trial for COVID-19 ARDS
On Sept. 2, 2020, Mesoblast announced that it had received ethics approval to include Australian hospitals in the…
-
Sanofi updated Kevzara (sarilumab) phase 3 trial in severe and critically ill COVID-19 patients outside the US
On Sept. 1, 2020, Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara (sarilumab) at…
-
Sanofi acquired Principia Biopharma for $3.68 billion
On Aug. 17, 2020, Sanofi and Principia Biopharma announced a definitive agreement under which Sanofi will acquire all…
-
Novavax and Takeda announced collaboration for Novavax COVID-19 vaccine candidate in Japan
On Aug. 7, 2020, Novavax and Takeda Pharmaceutical announced a partnership for the development, manufacturing and commercialization of…
-
RedHill Biopharma’s phase 2/3 COVID-19 study approved in Mexico
On Aug. 6, 2020, RedHill Biopharma announced approval from the Mexican Federal Committee for the Protection against Sanitary…
-
Cocrystal Pharma announced publication of positive data demonstrating potent in vitro inhibition against Coronavirus
On Aug. 4, 2020, Cocrystal Pharma announced the publication of preclinical animal studies of coronavirus antiviral compounds in…
-
US DFC announced $765 million loan to Eastman Kodak to support new expansion into pharmaceuticals
On Jul. 28, 2020, the U.S. International Development Finance Corp. (DFC) announced that it had signed a letter…
-
Sorrento Announced Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
On Jul. 20, 2020, Sorrento announced that its partner Mabpharm had received approval of its New Drug Application…
-
ViralClear partnered with Albany Molecular on manufacture of merimepodib API development for potential treatment of COVID-19
On Jul. 9, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma announced that it is partnering with Albany…
-
Corvus Pharmaceuticals initiated clinical trial of novel immunotherapy for patients with COVID-19
On Jul. 7, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
-
Fujifilm partnered with Dr. Reddy’s and Global Response Aid for deployment of a COVID-19 treatment drug outside of Japan
On Jul. 1, 2020, FUJIFILM announced a partnership with Dr. Reddy’s Laboratories, a global pharmaceutical company headquartered in…
-
Takeda received FDA approval to manufacture ENTYVIO (vedolizumab) drug substance at Brooklyn Park, Minnesota facility
On Jun. 23, 2020, Takeda Pharmaceutical announced that the FDA had approved the company’s submission for its biologics…
-
Catalent partnered with ViralClear Pharmaceuticals on potential treatment for COVID-19
On Jun. 22, 2020, Catalent announced that it had signed an agreement with ViralClear Pharmaceuticals, a subsidiary of…
-
FDA approved Bristol-Myers’ Opdivo’ (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinoma
On Jun. 11, 2020, Bristol-Myers Squibb announced that Opdivo (nivolumab) was approved by the FDA for the treatment…
-
Johnson & Johnson received positive CHMP opinion for Janssen’s investigational preventive Ebola vaccine regimen
On May 29, 2020, Johnson & Johnson announced that its Janssen Pharmaceutical subsidiary received a positive opinion from…
